Literature DB >> 7655990

Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats.

W Elwood1, J Sun, P J Barnes, M A Giembycz, K F Chung.   

Abstract

We examined the effect of a type IV (rolipram) and a combined type III and IV (Org 20421) isoenzyme-selective phosphodiesterase inhibitor upon allergen-induced pulmonary eosinophil recruitment in sensitised Brown Norway rats. Rats were sensitised with ovalbumin intraperitoneally and later challenged with ovalbumin aerosol which induced a significant increase in the total eosinophil and neutrophil count in bronchovalveolar lavage fluid at 24 hours (from 0.38 +/- 0.12 to 1.36 +/- 0.18 x 10(6), p < 0.01 and from 0.06 +/- 0.01 to 0.33 +/- 0.07 x 10(6), p < 0.01) respectively. Pretreatment with rolipram (30 mumol/kg) and Org 20421 (30 mumol/kg) abolished the eosinophilia and neutrophilia evoked by ovalbumin. We conclude that type IV and possibly type III isozyme phosphodiesterase inhibitors may regulate, directly or indirectly, eosinophil and neutrophil activity and/or those cells responsible for attracting them into the lung.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7655990     DOI: 10.1007/bf01793218

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  23 in total

1.  The relationship between late asthmatic responses and antigen-specific immunoglobulin.

Authors:  S Waserman; R Olivenstein; P Renzi; L J Xu; J G Martin
Journal:  J Allergy Clin Immunol       Date:  1992-10       Impact factor: 10.793

Review 2.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

3.  High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytes.

Authors:  S A Robicsek; J J Krzanowski; A Szentivanyi; J B Polson
Journal:  Biochem Biophys Res Commun       Date:  1989-08-30       Impact factor: 3.575

4.  Human recombinant lymphokines and cytokines induce pulmonary eosinophilia in the guinea pig which is inhibited by ketotifen and AH 21-132.

Authors:  M A Kings; I Chapman; A Kristersson; S Sanjar; J Morley
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

5.  Antigen challenge induces pulmonary airway eosinophil accumulation and airway hyperreactivity in sensitized guinea-pigs: the effect of anti-asthma drugs.

Authors:  S Sanjar; S Aoki; A Kristersson; D Smith; J Morley
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

6.  Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.

Authors:  D C Underwood; R R Osborn; L B Novak; J K Matthews; S J Newsholme; B J Undem; J M Hand; T J Torphy
Journal:  J Pharmacol Exp Ther       Date:  1993-07       Impact factor: 4.030

7.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

Authors:  G Dent; M A Giembycz; K F Rabe; P J Barnes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

8.  Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.

Authors:  J E Souness; C M Carter; B K Diocee; G A Hassall; L J Wood; N C Turner
Journal:  Biochem Pharmacol       Date:  1991-07-25       Impact factor: 5.858

9.  Rolipram inhibits PAF-induced airway microvascular leakage in guinea-pig: a comparison with milrinone and theophylline.

Authors:  J L Ortiz; J Cortijo; J M Vallés; E J Morcillo
Journal:  Fundam Clin Pharmacol       Date:  1992       Impact factor: 2.748

10.  Phospholipid and arachidonic acid metabolism in zymosan-stimulated human monocytes: modulation by cAMP.

Authors:  R W Godfrey; R M Manzi; D E Gennaro; S T Hoffstein
Journal:  J Cell Physiol       Date:  1987-06       Impact factor: 6.384

View more
  5 in total

1.  Phosphodiesterase 4 inhibition attenuates atrial natriuretic peptide-induced vascular hyperpermeability and loss of plasma volume.

Authors:  Yueh-Chen Lin; Haris Samardzic; Roger H Adamson; Eugene M Renkin; Joyce F Clark; Rolf K Reed; Fitz-Roy E Curry
Journal:  J Physiol       Date:  2010-11-22       Impact factor: 5.182

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Cyclic AMP elevating agents and nitric oxide modulate angiotensin II-induced leukocyte-endothelial cell interactions in vivo.

Authors:  A Alvarez; L Piqueras; M A Blazquez; M J Sanz
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

4.  Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice.

Authors:  Yueh-Chen Lin; Roger H Adamson; Joyce F Clark; Rolf K Reed; Fitz-Roy E Curry
Journal:  J Physiol       Date:  2011-11-14       Impact factor: 5.182

5.  Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation.

Authors:  María-Jesús Sanz; Angeles Alvarez; Laura Piqueras; Miguel Cerdá; Andrew C Issekutz; Roy R Lobb; Julio Cortijo; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.